Skip to main content
SpringerLink
Log in

Human Papillomavirus Vaccines

  • Chapter
  • First Online:
Human Papillomavirus

  • 977 Accesses

Abstract

Human papillomavirus (HPV) infection and HPV-associated anogenital diseases, such as warts, cancers precursors, as well as anogenital invasive cancers, are significant health care problems (Fig. 11.1). Current estimates of the worldwide prevalence of HPV indicate that approximately 10% of women in the general population will harbor cervical HPV infection at a given time (de Sanjose et al., 2007). Furthermore, estimates of human cancer incidence linked to infectious agents suggest that HPV infections in female individuals presently contribute to more than 51% of cancer cases, whereas infection in male individuals accounts for slightly more than 4% of HPV-associated neoplasias (Hausen, 2008). Cervical cancer causes considerable morbidity and mortality in the young female population and con­stitutes a significant economic burden to developing countries. According to 2002 data from the International Agency for Research on Cancer (Parkin et al., 2005), approximately half a million women worldwide develop cervical cancer every year (Fig. 11.1), and over two-thirds of these cases are associated with HPV infection of either oncogenic type 16 (51.0%) or HPV type 18 (16.2%). Consequently, successful strategies that can protect against HPV infection are expected to decrease the rates of HPV-related diseases. Sexual abstinence is the most effective preventive measure against HPV infection and other sexually transmitted diseases (STDs). Although Winer et al. (2006) reported that the regular use of condoms may reduce the risk of genital HPV infection, transmission to the unprotected perigenital skin can still occur.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Agarwal SS, Sehgal A, Sardana S, Kumar A, Luthra UK (1993) Role of male behavior in cervical carcinogenesis among women with one lifetime sexual partner. Cancer 72: 1666–1669

    Article  PubMed  CAS  Google Scholar 

  • Agosti JM, Goldie SJ (2007) Introducing HPV vaccine in developing countries – key challenges and issues. N Engl J Med 356: 1908–1910

    Article  PubMed  CAS  Google Scholar 

  • Ault KA (2007) Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: A combined analysis of four randomised clinical trials. Lancet 369: 1861–1868

    Article  PubMed  CAS  Google Scholar 

  • Baldwin PJ, van der Burg SH, Boswell CM, Offringa R, Hickling JK, Dobson J, Roberts JS, Latimer JA, Moseley RP, Coleman N, Stanley MA, Sterling JC (2003) Vaccinia-expressed human papillomavirus 16 and 18 e6 and e7 as a therapeutic vaccination for vulval and vaginal intraepithelial neoplasia. Clin Cancer Res 9: 5205–5213

    PubMed  CAS  Google Scholar 

  • Bierl C, Karem K, Poon AC, Swan D, Tortolero-Luna G, Follen M, Wideroff L, Unger ER, Reeves WC (2005) Correlates of cervical mucosal antibodies to human papillomavirus 16: Results from a case control study. Gynecol Oncol 99: S262–S268

    Article  PubMed  CAS  Google Scholar 

  • Block SL, Nolan T, Sattler C, Barr E, Giacoletti KE, Marchant CD, Castellsague X, Rusche SA, Lukac S, Bryan JT, Cavanaugh PF, Jr., Reisinger KS (2006) Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics 118: 2135–2145

    Article  PubMed  Google Scholar 

  • Bontkes HJ, de Gruijl TD, Walboomers JM, Schiller JT, Dillner J, Helmerhorst TJ, Verheijen RH, Scheper RJ, Meijer CJ (1999) Immune responses against human papillomavirus (HPV) type 16 virus-like particles in a cohort study of women with cervical intraepithelial neoplasia II. Systemic but not local IgA responses correlate with clearance of HPV-16. J Gen Virol 80(Pt 2): 409–417

    PubMed  CAS  Google Scholar 

  • Bosch FX, Castellsague X, de Sanjose S (2008) HPV and cervical cancer: Screening or vaccination? Br J Cancer 98: 15–21

    Article  PubMed  CAS  Google Scholar 

  • Bosch FX, Castellsague X, Munoz N, de Sanjose S, Ghaffari AM, Gonzalez LC, Gili M, Izarzugaza I, Viladiu P, Navarro C, Vergara A, Ascunce N, Guerrero E, Shah KV (1996) Male sexual behavior and human papillomavirus DNA: Key risk factors for cervical cancer in Spain. J Natl Cancer Inst 88: 1060–1067

    Article  PubMed  CAS  Google Scholar 

  • Bosch FX, Lorincz A, Munoz N, Meijer CJ, Shah KV (2002) The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 55: 244–265

    Article  PubMed  CAS  Google Scholar 

  • Brotherton JM, Gold MS, Kemp AS, McIntyre PB, Burgess MA, Campbell-Lloyd S (2008) Anaphylaxis following quadrivalent human papillomavirus vaccination. CMAJ 179: 525–533

    Article  PubMed  Google Scholar 

  • Brown D (2007) HPV type 6/11/16/18 vaccine: First analysis of cross-protection against persistent infection, cervical intraepithelial neoplasia (CIN), and adenocarcinoma in situ (AIS) caused by oncogenic HPV types in addition to 16/18 In: 47th Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago

    Google Scholar 

  • Brown DR, Bryan JT, Schroeder JM, Robinson TS, Fife KH, Wheeler CM, Barr E, Smith PR, Chiacchierini L, DiCello A, Jansen KU (2001) Neutralization of human papillomavirus type 11 (HPV-11) by serum from women vaccinated with yeast-derived HPV-11 L1 virus-like particles: correlation with competitive radioimmunoassay titer. J Infect Dis 184: 1183–1186

    Article  PubMed  CAS  Google Scholar 

  • Brown DR, Shew ML, Qadadri B, Neptune N, Vargas M, Tu W, Juliar BE, Breen TE, Fortenberry JD (2005) A longitudinal study of genital human papillomavirus infection in a cohort of closely followed adolescent women. J Infect Dis 191: 182–192

    Article  PubMed  Google Scholar 

  • Carter JJ, Koutsky LA, Hughes JP, Lee SK, Kuypers J, Kiviat N, Galloway DA (2000) Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection. J Infect Dis 181: 1911–1919

    Article  PubMed  CAS  Google Scholar 

  • Castellsague X, Bosch FX, Munoz N, Meijer CJ, Shah KV, de Sanjose S, Eluf-Neto J, Ngelangel CA, Chichareon S, Smith JS, Herrero R, Moreno V, Franceschi S (2002) Male circumcision, penile human papillomavirus infection, and cervical cancer in female partners. N Engl J Med 346: 1105–1112

    Article  PubMed  Google Scholar 

  • CDC HPV Vaccine Information for Clinicians. Centers for Disease Control and Prevention, Atlanta

    Google Scholar 

  • Christensen ND, Reed CA, Cladel NM, Han R, Kreider JW (1996) Immunization with virus like particles induces long-term protection of rabbits against challenge with cottontail rabbit papillomavirus. J Virol 70: 960–965

    PubMed  CAS  Google Scholar 

  • ClinicalTrials.gov In. U.S. National Institutes of Health

    Google Scholar 

  • Daling JR, Madeleine MM, Johnson LG, Schwartz SM, Shera KA, Wurscher MA, Carter JJ, Porter PL, Galloway DA, McDougall JK, Krieger JN (2005) Penile cancer: Importance of circumcision, human papillomavirus and smoking in in situ and invasive disease. Int J Cancer 116: 606–616

    Article  PubMed  CAS  Google Scholar 

  • Dasbach EJ, Insinga RP, Elbasha EH (2008) The epidemiological and economic impact of a quadrivalent human papillomavirus vaccine (6/11/16/18) in the UK. BJOG 115: 947–956

    Article  PubMed  CAS  Google Scholar 

  • Davidson EJ, Boswell CM, Sehr P, Pawlita M, Tomlinson AE, McVey RJ, Dobson J, Roberts JS, Hickling J, Kitchener HC, Stern PL (2003) Immunological and clinical responses in women with vulval intraepithelial neoplasia vaccinated with a vaccinia virus encoding human papillomavirus 16/18 oncoproteins. Cancer Res 63: 6032–6041

    PubMed  CAS  Google Scholar 

  • Day PM, Roden RB, Lowy DR, Schiller JT (1998) The papillomavirus minor capsid protein, L2, induces localization of the major capsid protein, L1, and the viral transcription/replication protein, E2, to PML oncogenic domains. J Virol 72: 142–150

    PubMed  CAS  Google Scholar 

  • Day PM, Thompson CD, Buck CB, Pang YY, Lowy DR, Schiller JT (2007) Neutralization of human papillomavirus with monoclonal antibodies reveals different mechanisms of inhibition. J Virol 81: 8784–8792

    Article  PubMed  CAS  Google Scholar 

  • de Gruijl TD, Bontkes HJ, Walboomers JM, Schiller JT, Stukart MJ, Groot BS, Chabaud MM, Remmink AJ, Verheijen RH, Helmerhorst TJ, Meijer CJ, Scheper RJ (1997) Immuno­globulin G responses against human papillomavirus type 16 virus-like particles in a prospective nonintervention cohort study of women with cervical intraepithelial neoplasia. J Natl Cancer Inst 89: 630–638

    Article  PubMed  CAS  Google Scholar 

  • de Jong A, van Poelgeest MI, van der Hulst JM, Drijfhout JW, Fleuren GJ, Melief CJ, Kenter G, Offringa R, van der Burg SH (2004) Human papillomavirus type 16-positive cervical cancer is associated with impaired CD4 + T-cell immunity against early antigens E2 and E6. Cancer Res 64: 5449–5455

    Article  PubMed  CAS  Google Scholar 

  • de Sanjose S, Diaz M,Castellsague X, Castellsague X, Clifford G, Bruni L, Munoz N, Bosch FX (2007) Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: A meta-analysis. Lancet Infect Dis 7: 453 – 459

    Article  PubMed  Google Scholar 

  • de Villiers EM, Fauquet C, Broker TR, Bernard HU, zur Hausen H (2004) Classification of papillomaviruses. Virology 324: 17–27

    Article  PubMed  CAS  Google Scholar 

  • de Witte L, Zoughlami Y, Aengeneyndt B, David G, van Kooyk Y, Gissmann L, Geijtenbeek TB (2007) Binding of human papilloma virus L1 virus-like particles to dendritic cells is mediated through heparan sulfates and induces immune activation. Immunobiology 212: 679–691

    Article  PubMed  CAS  Google Scholar 

  • D’Souza G, Kreimer AR, Viscidi R, Pawlita M, Fakhry C, Koch WM, Westra WH, Gillison ML (2007) Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med 356: 1944–1956

    Article  PubMed  Google Scholar 

  • Evander M, Frazer IH, Payne E, Qi YM, Hengst K, McMillan NA (1997) Identification of the alpha6 integrin as a candidate receptor for papillomaviruses. J Virol 71: 2449–2456

    PubMed  CAS  Google Scholar 

  • FDA, (2008) Gardasil – Product Approval Information. U.S. Food and Drug Administration, Rockville

    Google Scholar 

  • Frazer IH (2004) Prevention of cervical cancer through papillomavirus vaccination. Nat Rev Immunol 4: 46–54

    Article  PubMed  CAS  Google Scholar 

  • Frisch M, Fenger C, van den Brule AJ, Sorensen P, Meijer CJ, Walboomers JM, Adami HO, Melbye M, Glimelius B (1999) Variants of squamous cell carcinoma of the anal canal and perianal skin and their relation to human papillomaviruses. Cancer Res 59: 753–757

    PubMed  CAS  Google Scholar 

  • Future II Study Group (2007b) Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 356: 1915–1927

    Article  Google Scholar 

  • Gall S, Teixeira J (2007) Substantial impact on precancerous lesions and HPV infections through 5.5 years in women vaccinated with the HPV-16/18 L1 VLPAS04 candidate vaccine. In: Proceedings of the AACR Annual Meeting Los Angeles

    Google Scholar 

  • Gambhira R, Gravitt PE, Bossis I, Stern PL, Viscidi RP, Roden RB (2006) Vaccination of healthy volunteers with human papillomavirus type 16 L2E7E6 fusion protein induces serum antibody that neutralizes across papillomavirus species. Cancer Res 66: 11120–11124

    Article  PubMed  CAS  Google Scholar 

  • Gambhira R, Karanam B, Jagu S, Roberts JN, Buck CB, Bossis I, Alphs H, Culp T, Christensen ND, Roden RB (2007) A protective and broadly cross-neutralizing epitope of human papillomavirus. L2J Virol 81: 13927–13931

    Article  PubMed  CAS  Google Scholar 

  • Gavialliance In. GAVI Alliance

    Google Scholar 

  • Giannini SL, Hanon E, Moris P, Van Mechelen M, Morel S, Dessy F, Fourneau MA, Colau B, Suzich J, Losonksy G, Martin MT, Dubin G, Wettendorff MA (2006) Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. Vaccine 24: 5937–5949

    Article  PubMed  CAS  Google Scholar 

  • Gillison ML, Koch WM, Capone RB, Spafford M, Westra WH, Wu L, Zahurak ML, Daniel RW, Viglione M, Symer DE, Shah KV, Sidransky D (2000) Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst 92: 709–720

    Article  PubMed  CAS  Google Scholar 

  • Giuliano A, Palefsky J (2008) The efficacy of quadrivalent HPV (types 6/11/16/18) vaccine in reducing the incidence of HPV infection and HPV-related genital disease in young men In: European Research Organization on Genital Infection and Neoplasia – EUROGIN Nice, France

    Google Scholar 

  • Goldie SJ, O’Shea M, Campos NG, Diaz M, Sweet S, Kim SY (2008) Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries. Vaccine 26: 4080–4093

    Article  PubMed  Google Scholar 

  • Greer CE, Wheeler CM, Ladner MB, Beutner K, Coyne MY, Liang H, Langenberg A, Yen TS, Ralston R (1995) Human papillomavirus (HPV) type distribution and serological response to HPV type 6 virus-like particles in patients with genital warts. J Clin Microbiol 33: 2058–2063

    PubMed  CAS  Google Scholar 

  • Hagensee ME, Yaegashi N, Galloway DA (1993) Self-assembly of human papillomavirus type 1 capsids by expression of the L1 protein alone or by coexpression of the L1 and L2 capsid proteins. J Virol 67: 315–322

    PubMed  CAS  Google Scholar 

  • Hallez S, Simon P, Maudoux F, Doyen J, Noel JC, Beliard A, Capelle X, Buxant F, Fayt I, Lagrost AC, Hubert P, Gerday C, Burny A, Boniver J, Foidart JM, Delvenne P, Jacobs N (2004) Phase I/II trial of immunogenicity of a human papillomavirus (HPV) type 16 E7 protein-based vaccine in women with oncogenic HPV-positive cervical intraepithelial neoplasia. Cancer Immunol Immunother 53: 642–650

    Article  PubMed  CAS  Google Scholar 

  • Hampl M, Sarajuuri H, Wentzensen N, Bender HG, Kueppers V (2006) Effect of human papillomavirus vaccines on vulvar, vaginal, and anal intraepithelial lesions and vulvar cancer. Obstet Gynecol 108: 1361–1368

    Article  PubMed  CAS  Google Scholar 

  • Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, Schuind A, Zahaf T, Innis B, Naud P, De Carvalho NS, Roteli-Martins CM, Teixeira J, Blatter MM, Korn AP, Quint W, Dubin G (2004) Efficacy of a bivalent L1 virus-like ­particle vaccine in prevention of infection with human ­papillomavirus types 16 and 18 in young women: A randomised controlled trial. Lancet 364: 1757–1765

    Article  PubMed  CAS  Google Scholar 

  • Harper DM, Franco EL, Wheeler CM, Moscicki AB, Romanowski B, Roteli-Martins CM, Jenkins D, Schuind A, Costa Clemens SA, Dubin G (2006) Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: Follow-up from a randomised control trial. Lancet 367: 1247–1255

    Article  PubMed  CAS  Google Scholar 

  • Harro CD, Pang YY, Roden RB, Hildesheim A, Wang Z, Reynolds MJ, Mast TC, Robinson R, Murphy BR, Karron RA, Dillner J, Schiller JT, Lowy DR (2001) Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. J Natl Cancer Inst 93: 284–292

    Article  PubMed  CAS  Google Scholar 

  • Hausen HZ (2008) Papillomaviruses to vaccination and beyond. Biochemistry (Mosc) 73: 498–503

    Article  CAS  Google Scholar 

  • Hemminki K, Dong C, Frisch M (2000) Tonsillar and other upper aerodigestive tract cancers among cervical cancer patients and their husbands. Eur J Cancer Prev 9: 433–437

    Article  PubMed  CAS  Google Scholar 

  • Hildesheim A, Herrero R, Wacholder S, Rodriguez AC, Solomon D, Bratti MC, Schiller JT, Gonzalez P, Dubin G, Porras C, Jimenez SE, Lowy DR (2007) Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: A randomized trial. JAMA 298: 743–753

    Article  PubMed  CAS  Google Scholar 

  • Ho GY, Studentsov YY, Bierman R, Burk RD (2004) Natural history of human papillomavirus type 16 virus-like particle antibodies in young women. Cancer Epidemiol Biomarkers Prev 13: 110–116

    Article  PubMed  CAS  Google Scholar 

  • Huh WK, Roden RB (2008) The future of vaccines for cervical cancer. Gynecol Oncol 109: S48–S56

    Article  PubMed  CAS  Google Scholar 

  • Hung CF, Ma B, Monie A, Tsen SW, Wu TC (2008) Therapeutic human papillomavirus vaccines: Current clinical trials and future directions. Expert Opin Biol Ther 8: 421–439

    Article  PubMed  CAS  Google Scholar 

  • Insinga RP, Dasbach EJ, Elbasha EH, Puig A, Reynales-Shigematsu LM (2007) Cost-effectiveness of quadrivalent human ­papillomavirus (HPV) vaccination in Mexico: A transmission dynamic model-based evaluation. Vaccine 26: 128–139

    Article  PubMed  Google Scholar 

  • Joseph DA, Miller JW, Wu X, Chen VW, Morris CR, Goodman MT, Villalon-Gomez JM, Williams MA, Cress RD (2008) Understanding the burden of human papillomavirus-associated anal cancers in the US. Cancer 113: 2892–2900

    Article  PubMed  Google Scholar 

  • Joura EA, Leodolter S, Hernandez-Avila M, Wheeler CM, Perez G, Koutsky LA, Garland SM, Harper DM, Tang GW, Ferris DG, Steben M, Jones RW, Bryan J, Taddeo FJ, Bautista OM, Esser MT, Sings HL, Nelson M, Boslego JW, Sattler C, Barr E, Paavonen J (2007) Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: A combined analysis of three randomised clinical trials. Lancet 369: 1693–1702

    Article  PubMed  CAS  Google Scholar 

  • Kadish AS, Timmins P, Wang Y, Ho GY, Burk RD, Ketz J, He W, Romney SL, Johnson A, Angeletti R, Abadi M (2002) Regression of cervical intraepithelial neoplasia and loss of human papillomavirus (HPV) infection is associated with cell-mediated immune responses to an HPV type 16 E7 peptide. Cancer Epidemiol Biomarkers Prev 11: 483–488

    PubMed  CAS  Google Scholar 

  • Kagawa R, Yamaguchi T, Furuta R (2006) Histological features of human papilloma virus 16 and its association with the development and progression of anal squamous cell carcinoma. Surg Today 36: 885–891

    Article  PubMed  CAS  Google Scholar 

  • Kemp TJ, Hildesheim A, Falk RT, Schiller JT, Lowy DR, Rodriguez AC, Pinto LA (2008) Evaluation of two types of sponges used to collect cervical secretions and assessment of antibody extraction protocols for recovery of neutralizing anti-human papillomavirus type 16 antibodies. Clin Vaccine Immunol 15: 60–64

    Article  PubMed  CAS  Google Scholar 

  • Kim JJ, Andres-Beck B, Goldie SJ (2007) The value of ­including boys in an HPV vaccination programme: A cost-­effectiveness analysis in a low-resource setting. Br J Cancer 97: 1322–1328

    Article  PubMed  CAS  Google Scholar 

  • Kirnbauer R, Booy F, Cheng N, Lowy DR, Schiller JT (1992) Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc Natl Acad Sci U S A 89: 12180–12184

    Article  PubMed  CAS  Google Scholar 

  • Klencke B, Matijevic M, Urban RG, Lathey JL, Hedley ML, Berry M, Thatcher J, Weinberg V, Wilson J, Darragh T, Jay N, Da Costa M, Palefsky JM (2002) Encapsulated plasmid DNA treatment for human papillomavirus 16-associated anal dysplasia: A Phase I study of. ZYC101Clin Cancer Res 8: 1028–1037

    PubMed  CAS  Google Scholar 

  • Kondo K, Ochi H, Matsumoto T, Yoshikawa H, Kanda T (2008) Modification of human papillomavirus-like particle vaccine by insertion of the cross-reactive L2-epitopes. J Med Virol 80: 841–846

    Article  PubMed  CAS  Google Scholar 

  • Koutsky LA, Harper DM (2006) Chap. 13: Current findings from prophylactic HPV vaccine trials. Vaccine 24(Suppl 3): S3/114–S3/121

    CAS  Google Scholar 

  • Kreimer AR, Clifford GM, Boyle P, Franceschi S (2005) Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev 14: 467–475

    Article  PubMed  CAS  Google Scholar 

  • Laurence J (2008) HPV-linked oral cancer: another argument for universal HPV vaccination of boys and girls. AIDS Read 18: 345–346

    PubMed  Google Scholar 

  • Lee BN, Follen M, Shen DY, Malpica A, Adler-Storthz K, Shearer WT, Reuben JM (2004) Depressed type 1 cytokine synthesis by superantigen-activated CD4 + T cells of women with human papillomavirus-related high-grade squamous intraepithelial lesions. Clin Diagn Lab Immunol 11: 239–244

    PubMed  CAS  Google Scholar 

  • Lehtinen M, Apter D, Dubin G, Kosunen E, Isaksson R, Korpivaara EL, Kyha-Osterlund L, Lunnas T, Luostarinen T, Niemi L, Palmroth J, Petaja T, Rekonen S, Salmivesi S, Siitari-Mattila M, Svartsjo S, Tuomivaara L, Vilkki M, Pukkala E, Paavonen J (2006a) Enrolment of 22,000 adolescent women to cancer registry follow-up for long-term human papillomavirus vaccine efficacy: guarding against guessing. Int J STD AIDS 17: 517–521

    Article  PubMed  Google Scholar 

  • Lehtinen M, Idanpaan-Heikkila I, Lunnas T, Palmroth J, Barr E, Cacciatore R, Isaksson R, Kekki M, Koskela P, Kosunen E, Kuortti M, Lahti L, Liljamo T, Luostarinen T, Apter D, Pukkala E, Paavonen J (2006b) Population-based enrolment of adolescents in a long-term follow-up trial of human papillomavirus vaccine efficacy. Int J STD AIDS 17: 237–246

    Article  PubMed  CAS  Google Scholar 

  • Lin YY, Alphs H, Hung CF, Roden RB, Wu TC (2007) Vaccines against human papillomavirus. Front Biosci 12: 246–264

    Article  PubMed  CAS  Google Scholar 

  • Luna J, Saah A (2007) Safety, efficacy, and immunogenicity of quadrivalent HPV vaccine (Gardasil) in women aged 24–45.In: 24th International Papillomavirus Congress, Beijing

    Google Scholar 

  • Markowitz LE, Dunne EF, Saraiya M, Lawson HW, Chesson H, Unger ER (2007) Quadrivalent human papillomavirus ­vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 56: 1–24

    PubMed  Google Scholar 

  • May J (2007) HPV vaccination – a paradigm shift in public health. Aust Fam Physician 36: 106–111

    PubMed  Google Scholar 

  • Mbulawa ZZ, Williamson AL, Stewart D, Passmore JA, Denny L, Allan B, Marais DJ (2008) Association of serum and mucosal neutralizing antibodies to human papillomavirus type 16 (HPV-16) with HPV-16 infection and cervical disease. J Gen Virol 89: 910–914

    Article  PubMed  CAS  Google Scholar 

  • McMurray HR, Nguyen D, Westbrook TF, McAnce DJ (2001) Biology of human papillomaviruses. Int J Exp Pathol 82: 15–33

    Article  PubMed  CAS  Google Scholar 

  • MediLexicon International Ltd (2008) Gardasil® applies for WHO certification to reinforce global access to the vaccine – Approval would qualify Gardasil® for procurement by United. medicalnewstoday.

    Google Scholar 

  • Munger K, Baldwin A, Edwards KM, Hayakawa H, Nguyen CL, Owens M, Grace M, Huh K (2004) Mechanisms of human papillomavirus-induced oncogenesis. J Virol 78: 11451–11460

    Article  PubMed  CAS  Google Scholar 

  • Munger K, Howley PM (2002) Human papillomavirus immortalization and transformation functions. Virus Res 89: 213–228

    Article  PubMed  CAS  Google Scholar 

  • Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, Snijders PJ, Meijer CJ (2003) Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348: 518–527

    Article  PubMed  Google Scholar 

  • Nardelli-Haefliger D, Wirthner D, Schiller JT, Lowy DR, Hildesheim A, Ponci F, De Grandi P (2003) Specific antibody levels at the cervix during the menstrual cycle of women vaccinated with human papillomavirus 16 virus-like particles. J Natl Cancer Inst 95: 1128–1137

    Article  PubMed  Google Scholar 

  • Olsson SE, Villa LL, Costa RL, Petta CA, Andrade RP, Malm C, Iversen OE, Hoye J, Steinwall M, Riis-Johannessen G, Andersson-Ellstrom A, Elfgren K, von Krogh G, Lehtinen M, Paavonen J, Tamms GM, Giacoletti K, Lupinacci L, Esser MT, Vuocolo SC, Saah AJ, Barr E (2007) Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. Vaccine 25: 4931–4939

    Article  PubMed  CAS  Google Scholar 

  • Paavonen J, Jenkins D, Bosch FX, Naud P, Salmeron J, Wheeler CM, Chow SN, Apter DL, Kitchener HC, Castellsague X, de Carvalho NS, Skinner SR, Harper DM, Hedrick JA, Jaisamrarn U, Limson GA, Dionne M, Quint W, Spiessens B, Peeters P, Struyf F, Wieting SL, Lehtinen MO, Dubin G (2007) Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: An interim analysis of a phase III double-blind, randomised controlled trial. Lancet 369: 2161–2170

    Article  PubMed  CAS  Google Scholar 

  • Palefsky J, Giuliano A (2008) Efficacy of the quadrivalent HPV vaccine against HPV 6/11/16/18-related genital infection in young men In: European Research Organization on Genital Infection and Neoplasia – EUROGIN, Nice, France

    Google Scholar 

  • Pan American Health Organization (2008) Burden of Human Papillomavirus (HPV) Infection and HPV-Related Disease in Latin America and the Caribbean, and Health and Economic Outcomes of HPV Vaccination in Selected Countries in LatinAmerica, Executive Summary. Pan American Health Organization, Washington

    Google Scholar 

  • Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55: 74–108

    Article  PubMed  Google Scholar 

  • Parr EL, Parr MB (1997) Immunoglobulin G is the main protective antibody in mouse vaginal secretions after vaginal immunization with attenuated herpes simplex virus type 2. J Virol 71: 8109–8115

    PubMed  CAS  Google Scholar 

  • Partridge JM, Koutsky LA (2006) Genital human papillomavirus infection in men. Lancet Infect Dis 6: 21–31

    Article  PubMed  Google Scholar 

  • Pascual A, Pariente M, Godinez JM, Sanchez-Prieto R, Atienzar M, Segura M, Poblet E (2007) High prevalence of human papillomavirus 16 in penile carcinoma. Histol Histopathol 22: 177–183

    PubMed  CAS  Google Scholar 

  • Perez G, Lazcano-Ponce E, Hernandez-Avila M, Garcia PJ, Munoz N, Villa LL, Bryan J, Taddeo FJ, Lu S, Esser MT, Vuocolo S, Sattler C, Barr E (2008) Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like-particle vaccine in Latin American women. Int J Cancer 122: 1311–1318

    Article  PubMed  CAS  Google Scholar 

  • Piketty C, Kazatchkine MD (2005) Human papillomavirus-related cervical and anal disease in HIV-infected individuals in the era of highly active antiretroviral therapy. Curr HIV/AIDS Rep 2: 140–145

    Article  PubMed  Google Scholar 

  • Prowse DM, Ktori EN, Chandrasekaran D, Prapa A, Baithun S (2008) Human papillomavirus-associated increase in p16INK4A expression in penile lichen sclerosus and squamous cell carcinoma. Br J Dermatol 158: 261–265

    Article  PubMed  CAS  Google Scholar 

  • Qian X, Lu Y, Liu Q, Chen K, Zhao Q, Song J (2006) Prophy­lactic, therapeutic and anti-metastatic effects of an HPV-16mE6Delta/mE7/TBhsp70Delta fusion protein vaccine in an animal model. Immunol Lett 102: 191–201

    Article  PubMed  CAS  Google Scholar 

  • Rambout L, Hopkins L, Hutton B, Fergusson D (2007) Prophy­lactic vaccination against human papillomavirus infection and disease in women: A systematic review of randomized controlled trials. CMAJ 177: 469–479

    Article  PubMed  Google Scholar 

  • Reisinger KS, Block SL, Lazcano-Ponce E, Samakoses R, Esser MT, Erick J, Puchalski D, Giacoletti KE, Sings HL, Lukac S, Alvarez FB, Barr E (2007) Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents: A randomized controlled trial. Pediatr Infect Dis J 26: 201–209

    Article  PubMed  Google Scholar 

  • Ryding J, French KM, Naucler P, Barnabas RV, Garnett GP, Dillner J (2008) Seroepidemiology as basis for design of a human papillomavirus vaccination program. Vaccine 26: 5263–5268

    Article  PubMed  CAS  Google Scholar 

  • Ryerson AB, Peters ES, Coughlin SS, Chen VW, Gillison ML, Reichman ME, Wu X, Chaturvedi AK, Kawaoka K (2008) Burden of potentially human papillomavirus-associated cancers of the oropharynx and oral cavity in the US, ­1998–2003. Cancer 113: 2901–2909

    Article  PubMed  Google Scholar 

  • Sarkar AK, Tortolero-Luna G, Follen M, Sastry KJ (2005) Inverse correlation of cellular immune responses specific to synthetic peptides from the E6 and E7 oncoproteins of HPV-16 with recurrence of cervical intraepithelial neoplasia in a cross-sectional study. Gynecol Oncol 99: S251–S261

    Article  PubMed  CAS  Google Scholar 

  • Sasagawa T, Rose RC, Azar KK, Sakai A, Inoue M (2003) Mucosal immunoglobulin-A and -G responses to oncogenic human papilloma virus capsids. Int J Cancer 104: 328–335

    Article  PubMed  CAS  Google Scholar 

  • Saxenian H, Hecht R (2006) HPV vaccines: Costs and financing. In: Stop Cervical Cancer: Accelerating Global Access to HPV vaccines, London

    Google Scholar 

  • Schiffman M, Kjaer SK (2003) Chapter 2: Natural history of anogenital human papillomavirus infection and neoplasia. J Natl Cancer Inst Monogr (31): 14–19

    Article  PubMed  Google Scholar 

  • Schwartz SM, Daling JR, Doody DR, Wipf GC, Carter JJ, Madeleine MM, Mao EJ, Fitzgibbons ED, Huang S, Beckmann AM, McDougall JK, Galloway DA (1998) Oral cancer risk in relation to sexual history and evidence of human papillomavirus infection. J Natl Cancer Inst 90: 1626–1636

    Article  PubMed  CAS  Google Scholar 

  • Schwarz TF, Dubin G (2007) Human papillomavirus (HPV) 16/18 L1 AS04 virus-like particle (VLP) cervical cancer vaccine is immunogenic and well-tolerated 18 months after vaccination in women up to age 55 years. J Clin Oncol 25: abstract 3007

    Article  Google Scholar 

  • Schwarz TF, Leo O (2008) Immune response to human ­papillomavirus after prophylactic vaccination with AS04-adjuvanted HPV-16/18 vaccine: Improving upon nature. Gynecol Oncol 110: S1–S10

    Article  PubMed  CAS  Google Scholar 

  • Scott M, Stites DP, Moscicki AB (1999) Th1 cytokine patterns in cervical human papillomavirus infection. Clin Diagn Lab Immunol 6: 751–755

    PubMed  CAS  Google Scholar 

  • Sheets EE, Urban RG, Crum CP, Hedley ML, Politch JA, Gold MA, Muderspach LI, Cole GA, Crowley-Nowick PA (2003) Immunotherapy of human cervical high-grade cervical intraepithelial neoplasia with microparticle-delivered human papillomavirus 16 E7 plasmid DNA. Am J Obstet Gynecol 188: 916–926

    Article  PubMed  CAS  Google Scholar 

  • Sheu BC, Chang WC, Lin HH, Chow SN, Huang SC (2007) Immune concept of human papillomaviruses and related antigens in local cancer milieu of human cervical neoplasia. J Obstet Gynaecol Res 33: 103–113

    Article  PubMed  CAS  Google Scholar 

  • Skinner SR, Garland SM, Stanley MA, Pitts M, Quinn MA (2008) Human papillomavirus vaccination for the prevention of cervical neoplasia: Is it appropriate to vaccinate women older than 26? Med J Aust 188: 238–242

    PubMed  Google Scholar 

  • Slupetzky K, Gambhira R, Culp TD, Shafti-Keramat S, Schellenbacher C, Christensen ND, Roden RB, Kirnbauer R (2007) A papillomavirus-like particle (VLP) vaccine displaying HPV16 L2 epitopes induces cross-neutralizing antibodies to. HPV11Vaccine 25: 2001–2010

    Article  PubMed  CAS  Google Scholar 

  • Stanley M (2006) Immune responses to human papillomavirus. Vaccine 24(Suppl 1): S16–S22

    Article  PubMed  CAS  Google Scholar 

  • Stanley M, Coleman N, Chambers M (1994) The host response to lesions induced by human papillomavirus. Ciba Found Symp 187: 21–32; discussion 32–44

    PubMed  Google Scholar 

  • Stanley M, Lowy DR, Frazer I (2006) Chapter 12: Prophylactic HPV vaccines: Underlying mechanisms. Vaccine 24(Suppl 3): S3/106–S3/113

    CAS  Google Scholar 

  • Stanley MA, Pett MR, Coleman N (2007) HPV: From infection to cancer. Biochem Soc Trans 35: 1456–1460

    Article  PubMed  CAS  Google Scholar 

  • Streeck RE (2002) A short introduction to papillomavirus biology. Intervirology 45: 287–289

    Article  PubMed  Google Scholar 

  • Suzich JA, Ghim SJ, Palmer-Hill FJ, White WI, Tamura JK, Bell JA, Newsome JA, Jenson AB, Schlegel R (1995) Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc Natl Acad Sci U S A 92: 11553–11557

    Article  PubMed  CAS  Google Scholar 

  • Syrjanen KJ, Syrjanen SM (2000) Papillomavirus infections in human pathology. Wiley & Sons, Chichester, pp 11–51.

    Google Scholar 

  • Syrjanen S (2005) Human papillomavirus (HPV) in head and neck cancer. J Clin Virol 32(Suppl 1): S59–S66

    Article  PubMed  CAS  Google Scholar 

  • Tabrizi SN, Frazer IH, Garland SM (2006) Serologic response to human papillomavirus 16 among Australian women with high-grade cervical intraepithelial neoplasia. Int J Gynecol Cancer 16: 1032–1035

    Article  PubMed  CAS  Google Scholar 

  • Techakehakij W, Feldman RD (2008) Cost-effectiveness of HPV vaccination compared with Pap smear screening on a national scale: A literature review. Vaccine 26(49):6258–6265

    Article  PubMed  Google Scholar 

  • The Henry J. Kaiser Family Foundation (2007a) Public Health & Education | GSK Applies for WHO Prequalification of HPV Vaccine Cervarix. kaisernetwork.org.

    Google Scholar 

  • Transgene (2006) Sustained response at month 12 for transgene’s TG 4001 in HPV-induced precancerous lesions of the cervix and next clinical development steps. http://www.transgene.fr/us/pdf/communique_presse/communiques_divers_2006/PR-US_TG4001-HPV_13-11-2006.pdf

  • Trottier H, Franco EL (2006) The epidemiology of genital human papillomavirus infection. Vaccine 24(Suppl 1): S1–S15

    PubMed  Google Scholar 

  • Unckell F, Streeck RE, Sapp M (1997) Generation and neutralization of pseudovirions of human papillomavirus type 33. J Virol 71: 2934–2939

    PubMed  CAS  Google Scholar 

  • van Poelgeest MI, Nijhuis ER, Kwappenberg KM, Hamming IE, Wouter Drijfhout J, Fleuren GJ, van der Zee AG, Melief CJ, Kenter GG, Nijman HW, Offringa R, van der Burg SH (2006) Distinct regulation and impact of type 1 T-cell immunity against HPV16 L1, E2 and E6 antigens during HPV16-induced cervical infection and neoplasia. Int J Cancer 118: 675–683

    Article  PubMed  CAS  Google Scholar 

  • Varnai AD, Bollmann M, Griefingholt H, Speich N, Schmitt C, Bollmann R, Decker D (2006) HPV in anal squamous cell carcinoma and anal intraepithelial neoplasia (AIN). Impact of HPV analysis of anal lesions on diagnosis and prognosis. Int J Colorectal Dis 21: 135–142

    CAS  Google Scholar 

  • Villa LL (2007) Overview of the clinical development and results of a quadrivalent HPV (types 6, 11, 16, 18) vaccine. Int J Infect Dis 11(Suppl 2): S17–S25

    Article  PubMed  Google Scholar 

  • Villa LL, Costa RL, Petta CA, Andrade RP, Ault KA, Giuliano AR, Wheeler CM, Koutsky LA, Malm C, Lehtinen M, Skjeldestad FE, Olsson SE, Steinwall M, Brown DR, Kurman RJ, Ronnett BM, Stoler MH, Ferenczy A, Harper DM, Tamms GM, Yu J, Lupinacci L, Railkar R, Taddeo FJ, Jansen KU, Esser MT, Sings HL, Saah AJ, Barr E (2005) Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: A randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 6: 271–278

    Article  PubMed  Google Scholar 

  • Villa LL, Costa RL, Petta CA, Andrade RP, Paavonen J, Iversen OE, Olsson SE, Hoye J, Steinwall M, Riis-Johannessen G, Andersson-Ellstrom A, Elfgren K, Krogh G, Lehtinen M, Malm C, Tamms GM, Giacoletti K, Lupinacci L, Railkar R, Taddeo FJ, Bryan J, Esser MT, Sings HL, Saah AJ, Barr E (2006) High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer 95: 1459–1466

    Article  PubMed  CAS  Google Scholar 

  • Viscidi RP, Schiffman M, Hildesheim A, Herrero R, Castle PE, Bratti MC, Rodriguez AC, Sherman ME, Wang S, Clayman B, Burk RD (2004) Seroreactivity to human papillomavirus (HPV) types 16, 18, or 31 and risk of subsequent HPV infection: Results from a population-based study in Costa Rica. Cancer Epidemiol Biomarkers Prev 13: 324–327

    Article  PubMed  Google Scholar 

  • Viscidi RP, Snyder B, Cu-Uvin S, Hogan JW, Clayman B, Klein RS, Sobel J, Shah KV (2005) Human papillomavirus capsid antibody response to natural infection and risk of subsequent HPV infection in HIV-positive and HIV-negative women. Cancer Epidemiol Biomarkers Prev 14: 283–288

    PubMed  CAS  Google Scholar 

  • Watson M, Saraiya M, Ahmed F, Cardinez CJ, Reichman ME, Weir HK, Richards TB (2008) Using population-based ­cancer registry data to assess the burden of human ­papillomavirus-associated cancers in the United States: Overview of methods. Cancer 113: 2841–2854

    Article  PubMed  Google Scholar 

  • Weinberger PM, Yu Z, Haffty BG, Kowalski D, Harigopal M, Brandsma J, Sasaki C, Joe J, Camp RL, Rimm DL, Psyrri A (2006) Molecular classification identifies a subset of human Papillomavirus – associated oropharyngeal cancers with favorable prognosis. J Clin Oncol 24: 736–747

    Article  PubMed  CAS  Google Scholar 

  • Welters MJ, de Jong A, van den Eeden SJ, van der Hulst JM, Kwappenberg KM, Hassane S, Franken KL, Drijfhout JW, Fleuren GJ, Kenter G, Melief CJ, Offringa R, van der Burg SH (2003) Frequent display of human papillomavirus type 16 E6-specific memory T-helper cells in the healthy population as witness of previous viral encounter. Cancer Res 63: 636–641

    PubMed  CAS  Google Scholar 

  • Wentzensen N, Vinokurova S, von Knebel Doeberitz M (2004) Systematic review of genomic integration sites of human papillomavirus genomes in epithelial dysplasia and invasive cancer of the female lower genital tract. Cancer Res 64: 3878–3884

    Article  PubMed  CAS  Google Scholar 

  • Wheeler CM (2007) Advances in primary and secondary interventions for cervical cancer: human papillomavirus prophylactic vaccines and testing. Nat Clin Pract Oncol 4: 224–235

    Article  PubMed  Google Scholar 

  • WHO In. World Health Organization (WHO)

    Google Scholar 

  • WHO (1990) Sexually transmitted infections increasing – 250 million new infections annually. WHO Feature 152: 1–6

    Google Scholar 

  • WHO (1990) The current status of development of prophylactic vaccines against human papillomavirus infection. Report of a technical meeting, Geneva, 16–18 February 1999, pp 1–22

    Google Scholar 

  • WHO (2006) Comprehensive cervical cancer control: a guide to essential practice. World Health Organization p284

    Google Scholar 

  • Winer RL, Hughes JP, Feng Q, O’Reilly S, Kiviat NB, Holmes KK, Koutsky LA (2006) Condom use and the risk of genital human papillomavirus infection in young women. N Engl J Med 354: 2645–2654

    Article  PubMed  CAS  Google Scholar 

  • Xu Y, Wang Q, Han Y, Song G, Xu X (2007) Type-specific and cross-reactive antibodies induced by human papillomavirus 31 L1/L2 virus-like particles. J Med Microbiol 56: 907–913

    Article  PubMed  CAS  Google Scholar 

  • Xu Y, Zhang H, Xu X (2008) Enhancement of vaccine potency by fusing modified LTK63 into human papillomavirus type 16 chimeric virus-like particles. FEMS Immunol Med Microbiol 52: 99–109

    Article  PubMed  CAS  Google Scholar 

  • Zhou J, Sun XY, Stenzel DJ, Frazer IH (1991) Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles. Virology 185: 251–257

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Albert Einstein Jewish Hospital, Sao Paulo, Brasil

    Alberto Rosenblatt

Authors
  1. Alberto Rosenblatt
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Homero Gustavo de Campos Guidi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alberto Rosenblatt .

Rights and permissions

Reprints and permissions

Copyright information

© 2009 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Rosenblatt, A., de Campos Guidi, H.G. (2009). Human Papillomavirus Vaccines. In: Human Papillomavirus. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-70974-9_11

Download citation

  • DOI: https://doi.org/10.1007/978-3-540-70974-9_11

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-70973-2

  • Online ISBN: 978-3-540-70974-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation